News
ABPO
0.202
-8.18%
-0.018
Weekly Report: what happened at ABPO last week (0518-0522)?
Weekly Report · 11h ago
Weekly Report: what happened at ABPO last week (0511-0515)?
Weekly Report · 05/18 09:14
Abpro Holdings Delays Quarterly SEC Filing
TipRanks · 05/15 23:31
Weekly Report: what happened at ABPO last week (0504-0508)?
Weekly Report · 05/11 09:14
Weekly Report: what happened at ABPO last week (0427-0501)?
Weekly Report · 05/04 09:13
Weekly Report: what happened at ABPO last week (0420-0424)?
Weekly Report · 04/27 09:14
Weekly Report: what happened at ABPO last week (0413-0417)?
Weekly Report · 04/20 09:13
Weekly Report: what happened at ABPO last week (0406-0410)?
Weekly Report · 04/13 09:14
Weekly Report: what happened at ABPO last week (0330-0403)?
Weekly Report · 04/06 09:14
Abpro Holdings Delays Annual 10-K Filing
TipRanks · 03/31 18:11
Weekly Report: what happened at ABPO last week (0323-0327)?
Weekly Report · 03/30 09:14
Weekly Report: what happened at ABPO last week (0316-0320)?
Weekly Report · 03/23 09:13
Weekly Report: what happened at ABPO last week (0309-0313)?
Weekly Report · 03/16 09:13
Weekly Report: what happened at ABPO last week (0302-0306)?
Weekly Report · 03/09 09:13
Weekly Report: what happened at ABPO last week (0223-0227)?
Weekly Report · 03/02 09:13
*News On Abpro Holdings Inc. (ABP) Now Under ABPO
Dow Jones · 02/23 22:08
Weekly Report: what happened at ABP last week (0216-0220)?
Weekly Report · 02/23 09:13
Abpro Holdings Faces Nasdaq Delisting, Plans Appeal
TipRanks · 02/20 21:59
Nasdaq Orders Abpro Holdings Delisting for Minimum Equity Noncompliance
Reuters · 02/20 21:16
Weekly Report: what happened at ABP last week (0209-0213)?
Weekly Report · 02/16 09:13
More
Webull provides a variety of real-time ABPO stock news. You can receive the latest news about ABPRO HLDGS INC through multiple platforms. This information may help you make smarter investment decisions.
About ABPO
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).